Bristol-Myers Squibb gets FDA complete response letter for Belatacept
By New Statesman - 03 May 11:52

Bristol-Myers Squibb has received a Food and Drugs Agency (FDA) complete response letter about the b

Surge in American demand for ADHD drug boosts Shire
By New Statesman - 30 April 15:37

Drug's first-quarter sales up nearly a third on the same period last year, generating $154 million.

GlaxoSmithKline posts healthy profits
By Jennifer Thompson - 28 April 17:38

Swine flu vaccine helps boost pharmaceutical and healthcare company’s profits by 16 per cent in Q1.

Mobile Telesystems outsources network operations to Nokia Siemens
By New Statesman - 27 April 12:46

Russian operator hopes to simplify its overall network operations model.

Sectra sells synthetic magnetic resonance application to Switzerland
By New Statesman - 27 April 12:42

The software will enhance quality in conjunction with virtual autopsies.

Anacor Pharmaceuticals inks research agreement
By New Statesman - 27 April 12:28

Company reaches agreement with not-for-profit Medicines for Malaria Venture (MMV)

Intercell revenues up
By New Statesman - 27 April 12:24

Biotech firm reports revenues of EUR61.68m for the full year ended December 31, 2009,

FDA introduces initiative to reduce infusion pump risks
By New Statesman - 26 April 13:40

New initiative to address safety problems associated with external infusion pumps.

Nycomed, Merck & Co ink commercialisation agreements for Daxas
By New Statesman - 26 April 13:31

Co-promotion agreement for new drug

Biotage to take over MIP Technologies
By New Statesman - 26 April 13:24

Biotage to acquire shares for 16m Swedish Kronor

Abbott buys Facet Biotech
By New Statesman - 22 April 12:26

The health care company made the acquisition to strengthen its presence in immunology and oncology.

Micromet reaches milestone under collaboration agreement
By New Statesman - 22 April 12:20

The company has achieved a milestone under its collaboration agreement with Bayer Schering Pharma.

Eli Lilly announces revenue increase of 9 per cent
By New Statesman - 21 April 12:35

However earnings of the pharmaceuticals company were hit by US healthcare reform.

Genentech to pay Seattle Genetics under antibody-drug collaboration
By New Statesman - 21 April 12:29

$9.5m deal will see Genentech responsible for research.

DSM names new CEO
By New Statesman - 20 April 12:34

Alexander Wessels to become president and CEO of DSM Pharmaceutical Products.

Roche sales up 6 per cent
By New Statesman - 19 April 12:57

The healthcare firm's first quarter sales are up CHF12.2bn (Swiss Francs).

Oracle to buy Phase Forward for $685m
By New Statesman - 19 April 12:53

The company is to acquire the provider of data management solutions for $17 per share in cash.

Siemens Healthcare names new ultrasound territory manager
By New Statesman - 16 April 12:33

Peter Downing has been selected as North East Territory Manager for Ultrasound.

Stemgent and Pfizer sign agreement for research reagents
By New Statesman - 16 April 12:29

Stemgent will make reagents discovered or developed by Pfizer available to the global research commu

J&J whistleblower jailed over bribery scandal
By New Statesman - 15 April 13:36

Robert Dougall, a former director of marketing at a Johnson & Johnson subsidiary, has been jailed fo

Penwest signs agreement with Alvogen
By New Statesman - 12 April 12:07

The pharmaceutical companies have agreed to identify and select up to five compounds for generic dev

Biopartners gets EU authorisation
By New Statesman - 09 April 12:15

Pharmaceutical firm gets marketing authorisation for Ribavirin 200mg film-coated tablets

Sanofi-aventis and CureDM in $335m agreement
By New Statesman - 08 April 13:24

Sanofi-aventis and CureDM have entered into a global licence agreement on a new human peptide which

Emerging World Pharma invests in European Global Pharma
By New Statesman - 08 April 13:18

The investor has pumped funds into the pharmaceutical company for a generic drug manufacturing facil

CancerGuide Diagnostics enters licensing agreement with Duke
By New Statesman - 07 April 13:04

Research collaboration will develop individualised cancer treatment decisions.

BioAlliance Pharma signs license agreement with Therabel
By New Statesman - 06 April 14:35

The company has entered into an exclusive partnership with Therabel group, landing it €48.5m.

AnaptysBio collaborates with VLST
By New Statesman - 06 April 14:24

Companies come together to create therapeutics for the treatment of autoimmune and inflammatory diso

AtCor Medical enters into new pharmaceutical clinical trials pact
By New Statesman - 05 April 12:58

AtCor Medical, a developer and marketer of the SphygmoCor system has signed a $955,000 agreement wit

Eli Lilly receives positive recommendation from NICE for Alimta
By New Statesman - 05 April 12:55

Eli Lilly and Company has received a positive Final Appraisal Determination (FAD) for chemotherapy A

Pages